Viridian Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VRDN research report →
About the company
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED).
- CEO
- Stephen F. Mahoney
- IPO
- 2014
- Employees
- 143
- HQ
- Waltham, MA, US
Price Chart
- Market Cap
- $1.75B
- P/E
- -5.57
- P/S
- 24.62
- P/B
- 3.12
- EV/EBITDA
- -4.64
- Div Yield
- 0.00%
- Gross Margin
- 99.38%
- Op Margin
- -543.86%
- Net Margin
- -508.46%
- ROE
- -60.70%
- ROIC
- -52.27%
- Revenue
- $70.85M · 23359.93%
- Net Income
- $-342,601,000 · -26.91%
- EPS
- $-3.32 · 16.58%
- Op Income
- $-363,395,000
- FCF YoY
- -18.92%
- 52W High
- $34.29
- 52W Low
- $13.18
- 50D MA
- $16.46
- 200D MA
- $24.11
- Beta
- 0.90
- Avg Volume
- 2.87M
Get TickerSpark's AI analysis on VRDN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 1, 26 | CAIN CHRISTOPHER W. | other | 32,341 |
| Jul 1, 26 | Ajer Jeffrey Robert | other | 32,341 |
| Jul 1, 26 | Moses Jennifer K. | other | 32,341 |
| Jul 1, 26 | Gheuens Sarah | other | 32,341 |
| Jul 1, 26 | Kiselak Tomas | other | 32,341 |
| Jul 1, 26 | Morris Arlene | other | 32,341 |
| May 11, 26 | Fairmount Funds Management LLC | buy | 1,176,470 |
| Mar 3, 26 | Harmon Seth | other | 2,031 |
| Mar 3, 26 | Beetham Thomas W. | other | 3,048 |
| Mar 3, 26 | Tousignant Jennifer | other | 1,675 |
Our VRDN coverage
Recent articles, reports, and earnings notes.
No research on VRDN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VRDN report →Similar companies
Peers in the same neighborhood.